TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34080792

Group type: EXPERIMENTAL
Intervention: Directional atherectomy (DA) prior to drug coated balloon (DCB) angioplasty
Number of subjects: 102
Study: 34081015

Group type: EXPERIMENTAL
Intervention: Home health monitoring (HHM) technology for 60 days post-discharge.
Number of subjects: 70
Study: 34081059

Group type: EXPERIMENTAL
Intervention: Replacing 30 min·d-1 of ST with 30 min·d-1 of MVPA
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Replacing 30 min·d-1 of ST with 30 min·d-1 of LPA
Number of subjects: 228
Study: 34081125

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34081353

Group type: EXPERIMENTAL
Intervention: PICU admission
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with parents
Number of subjects: 110
Study: 34082006

Group type: EXPERIMENTAL
Intervention: Sirolimus (daily oral for 12 months)
Number of subjects: 126
Study: 34082024

Group type: EXPERIMENTAL
Intervention: Olaparib (PARP inhibitor)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Olaparib + AZD6738 (ATR inhibitor)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Olaparib + ceralasertib (ATR inhibitor)
Number of subjects: 10
Study: 34082253

Group type: EXPERIMENTAL
Intervention: SF-36 questionnaire assessment before admission and after one year
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: In-depth interviews with 19 purposively selected patients
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Thematic coding using the PROMIS framework
Number of subjects: 797
Study: 34082643

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine (GSK's seasonal inactivated influenza vaccines)
Number of subjects: 507
Study: 34082839

Group type: EXPERIMENTAL
Intervention: Prenatal Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 34083035

Group type: EXPERIMENTAL
Intervention: Alkaline comet assay (single cell gel electrophoresis)
Number of subjects: 19320

Group type: EXPERIMENTAL
Intervention: Age as a host factor
Number of subjects: 19320

Group type: EXPERIMENTAL
Intervention: Sex and smoking habit as confounders
Number of subjects: 19320

Group type: EXPERIMENTAL
Intervention: Exposure to genotoxic agents
Number of subjects: 19320
Study: 34083157

Group type: EXPERIMENTAL
Intervention: Topical radiographic contrast method using sodium iodide solution
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional bitewing (BW) examinations
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intraexaminer reliability for classifying lesions
Number of subjects: 22
Study: 34083209

Group type: EXPERIMENTAL
Intervention: New surveillance pathway with multimodal imaging reviewed by trained ophthalmic graders
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ultrawide field images
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Seven-field Early Treatment for Diabetic Retinopathy Study (ETDRS) images
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (face-to-face evaluation by an ophthalmologist)
Number of subjects: 100
Study: 34083230

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 106
Study: 34083232

Group type: EXPERIMENTAL
Intervention: PF-06647020 administered every 3 weeks at 2.8 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06647020 administered every 2 weeks at 2.1-3.2 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06647020 administered every 3 weeks at 0.2-3.7 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06647020 administered every 3 weeks at highest dose evaluated
Number of subjects: 0
Study: 34083236

Group type: EXPERIMENTAL
Intervention: CX-2029 at 4 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CX-2029 at 5 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CX-2029 at 4 mg/kg (expanded cohort)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CX-2029
Number of subjects: 45
Study: 34083340

Group type: EXPERIMENTAL
Intervention: STarT Back Screening Tool (SBST)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: STarT Back Screening Tool (SBST) with added work ability items
Number of subjects: 158
Study: 34083342

Group type: EXPERIMENTAL
Intervention: Social health insurance system (SHI)
Number of subjects: 7817

Group type: COMPARATOR
Intervention: Tax-based healthcare system (THS)
Number of subjects: 7817

Group type: EXPERIMENTAL
Intervention: Social health insurance system (SHI) in low GDP per capita settings
Number of subjects: 7817

Group type: EXPERIMENTAL
Intervention: Social health insurance system (SHI) in low HDI settings
Number of subjects: 7817
Study: 34083421

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously on days 1 and 15, with surgery planned by day 29.
Number of subjects: 52
Study: 34083595

Group type: EXPERIMENTAL
Intervention: Therapeutic hypercapnia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34083618

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day for 15 weeks
Number of subjects: 20
Study: 34083737

Group type: EXPERIMENTAL
Intervention: African-American men (AAM)
Number of subjects: 1152

Group type: COMPARATOR
Intervention: European-American men (EAM)
Number of subjects: 1152
Study: 34084608

Group type: EXPERIMENTAL
Intervention: Neurotechnology-based therapy (seizure advisory system)
Number of subjects: 400
Study: 34084993

Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Certain HMOs and bioactive proteins
Number of subjects: 0
Study: 34085287

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: CHM plus clomiphene
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: CHM plus follicle aspiration plus ovulation induction
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: CHM plus laparoscopic ovarian drilling (LOD)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Clomiphene (with or without LOD)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Control group (placebo, no treatment, or conventional therapies)
Number of subjects: 609
Study: 34085900

Group type: EXPERIMENTAL
Intervention: MenACYW-TT booster dose
Number of subjects: 91

Group type: COMPARATOR
Intervention: MCV4-TT primed group
Number of subjects: 91
Study: 34085949

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Older age and history of microvascular complications
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: CRP, AST, eGFR (CKD-EPI)
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Lymphocytopenia
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia and elevated plasma glucose concentration
Number of subjects: 2380
Study: 34086122

Group type: EXPERIMENTAL
Intervention: PHGG plus sodium hyaluronate (PHGG+)
Number of subjects: 34
Study: 34086171

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel 80 mg/m² with carboplatin, trastuzumab, and pertuzumab (wPCbTP)
Number of subjects: 30
Study: 34086266

Group type: EXPERIMENTAL
Intervention: COVID-19 group (n = 60)
Number of subjects: 60
Study: 34086408

Group type: EXPERIMENTAL
Intervention: Fludarabine-based reduced-intensity conditioning (RIC) regimen
Number of subjects: 9
Study: 34086494

Group type: EXPERIMENTAL
Intervention: Intermittently Scanned Continuous Glucose Monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real-Time Continuous Glucose Monitoring
Number of subjects: 0
Study: 34086503

Group type: EXPERIMENTAL
Intervention: COVID-19 management in children with diabetes
Number of subjects: 22820

Group type: EXPERIMENTAL
Intervention: Glycemic control measures
Number of subjects: 22820
Study: 34086623

Group type: EXPERIMENTAL
Intervention: Pediatric Evaluation of Disability Index-Computer Adapted Test (PEDI-CAT) mobility domain (PEDI-mob)
Number of subjects: 54
Study: 34086718

Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stable Coronary Artery Disease (CAD) subjects
Number of subjects: 0
Study: 34086865

Group type: EXPERIMENTAL
Intervention: ibrutinib/ofatumumab (IO)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ibrutinib/obinutuzumab (IG)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: venetoclax/obinutuzumab (AG)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Discontinuation due to uMRD
Number of subjects: 51
Study: 34086888

Group type: COMPARATOR
Intervention: Stage 0-1 (no cardiac damage or left ventricular damage)
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Stage 2 (left atrial or mitral valve damage)
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Stage 3 (pulmonary vasculature or tricuspid valve damage)
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Stage 4 (right ventricular damage or low-flow state)
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Stage 3b, Stage 4b, and Stage 4c
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Advanced cardiac damage (severe pulmonary hypertension or RV dysfunction)
Number of subjects: 1156
Study: 34087324

Group type: EXPERIMENTAL
Intervention: 2-year school-based intervention (PRALIMAP study)
Number of subjects: 3279
Study: 34087573

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg, twice daily)
Number of subjects: 252
Study: 34087863

Group type: EXPERIMENTAL
Intervention: NexfinTM (beat-to-beat noninvasive blood pressure monitoring)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Intermittent oscillometry (conventional method)
Number of subjects: 174
Study: 34087940

Group type: EXPERIMENTAL
Intervention: Total fructose-containing sugars in substitution trials
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (SSBs) in substitution design
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Sweets and desserts in substitution design
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (SSBs) in addition trials
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: 100% fruit juice in addition trials
Number of subjects: 2763
Study: 34087943

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KetoCal® KD, 90% fat, 8% carbohydrate, 2% protein)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KetoCal® KD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Radiation with concurrent platinum-based chemotherapy
Number of subjects: 12
Study: 34087967

Group type: EXPERIMENTAL
Intervention: Abdominal flap (DIEP, fTRAM, pTRAM)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Dorsal flap (LD, TDAP)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Other (TMG, implant)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Preoperative pain
Number of subjects: 121
Study: 34088579

Group type: EXPERIMENTAL
Intervention: Aggressive multiple sclerosis (aMS)
Number of subjects: 2158

Group type: COMPARATOR
Intervention: Non-aggressive multiple sclerosis (non-aMS)
Number of subjects: 2158
Study: 34088656

Group type: EXPERIMENTAL
Intervention: e-CBT program
Number of subjects: 15

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 15

Group type: COMPARATOR
Intervention: In-person CBT
Number of subjects: 15
Study: 34088726

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 80
Study: 34088733

Group type: EXPERIMENTAL
Intervention: Perioperative iron administration
Number of subjects: 0
Study: 34088741

Group type: EXPERIMENTAL
Intervention: Nivolumab and radiotherapy
Number of subjects: 17
Study: 34088789

Group type: EXPERIMENTAL
Intervention: Post-lockdown period
Number of subjects: 311
Study: 34088831

Group type: EXPERIMENTAL
Intervention: Venetoclax-based rational combinations
Number of subjects: 0
Study: 34089063

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for more than 24 hours
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Higher severity of illness (APACHE III)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Admission diagnosis (cardiac arrest)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Admission diagnosis (sepsis)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Admission diagnosis (trauma)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Admission diagnosis (lung transplant)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Model including age, illness severity, and admission diagnosis
Number of subjects: 628
Study: 34089087

Group type: EXPERIMENTAL
Intervention: POCUS protocol (US+)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No POCUS (US-)
Number of subjects: 100
Study: 34089097

Group type: EXPERIMENTAL
Intervention: Ectoin
Number of subjects: 0
Study: 34089325

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) program, 12-week exercise-based intervention.
Number of subjects: 359
Study: 34089500

Group type: EXPERIMENTAL
Intervention: Reinforcement of double-stapled anastomosis using circular mucosa plication and vacuum drainage with povidone-iodine-soaked sponge
Number of subjects: 54
Study: 34089610

Group type: EXPERIMENTAL
Intervention: Natural infection (COVID-19 convalescent donors)
Number of subjects: 228
Study: 34089650

Group type: EXPERIMENTAL
Intervention: Nusinersen (6 mg equivalent for cohort 1, 12 mg for cohort 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nusinersen (12 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 20
Study: 34089739

Group type: EXPERIMENTAL
Intervention: Early adherence to Low Tidal Volume Ventilation (LPV)
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Center management practices
Number of subjects: 2466
Study: 34089751

Group type: EXPERIMENTAL
Intervention: Preoperative stereotactic ablative body radiotherapy (SBRT) as 5 fractions of 7 Gy with dose reduction to 5 fractions of 5 Gy on tumor margins.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Postoperative conventional radiotherapy as standard compartmental irradiation in 25 fractions of 2 Gy, starting 5-8 weeks after surgery.
Number of subjects: 14
Study: 34089855

Group type: EXPERIMENTAL
Intervention: Domperidone (DOM) therapy
Number of subjects: 748
Study: 34089982

Group type: EXPERIMENTAL
Intervention: FXIa-AT complex (Q2 and Q3 quartiles)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: FIXa-AT complex
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: TAT complex
Number of subjects: 114
Study: 34090143

Group type: EXPERIMENTAL
Intervention: OncoMasTR Molecular Score (OMm)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: OncoMasTR Risk Score (OM)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: OncoMasTR scores (OMm and OM)
Number of subjects: 404
Study: 34090525

Group type: EXPERIMENTAL
Intervention: Training webinar
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Training + implementation enhanced resources (including a champion at each site and monthly peer support consultation calls)
Number of subjects: 19
Study: 34090853

Group type: EXPERIMENTAL
Intervention: Remote training for clinician trainers
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Training for able-bodied trainees
Number of subjects: 26
Study: 34090865

Group type: EXPERIMENTAL
Intervention: Nanotechnology-based strategies for cancer diagnosis and therapy
Number of subjects: 0
Study: 34090871

Group type: EXPERIMENTAL
Intervention: Operated patients undergoing pulmonary thromboendarterectomy (PTE) surgery (n = 566)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Operated patients
Number of subjects: 750

Group type: COMPARATOR
Intervention: Inoperable patients
Number of subjects: 750

Group type: COMPARATOR
Intervention: Operable patients who did not undergo surgery (n = 88)
Number of subjects: 750
Study: 34090872

Group type: EXPERIMENTAL
Intervention: Abdominal muscle ultrasound measurements during spontaneous breathing trial
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined thickening fraction of transversus abdominis, internal oblique, and rectus abdominis during cough
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Abdominal muscle thickening on ultrasound
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Abdominal muscle ultrasound measurements
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Reduced abdominal muscle thickening during cough
Number of subjects: 57
Study: 34091488

Group type: EXPERIMENTAL
Intervention: Oral insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34091519

Group type: EXPERIMENTAL
Intervention: Functional dyspepsia (FD)
Number of subjects: 2916

Group type: EXPERIMENTAL
Intervention: Organic dyspepsia (OD)
Number of subjects: 2916

Group type: COMPARATOR
Intervention: Helicobacter pylori infection rate in FD patients
Number of subjects: 2916

Group type: EXPERIMENTAL
Intervention: Frequent spicy food consumption
Number of subjects: 2916

Group type: EXPERIMENTAL
Intervention: Consumption of deep well water
Number of subjects: 2916
Study: 34091540

Group type: EXPERIMENTAL
Intervention: 3D-Transit system (Motilis SA, Lausanne, Switzerland)
Number of subjects: 21
Study: 34091867

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34091914

Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Number of subjects: 150

Group type: COMPARATOR
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: SBRT
Number of subjects: 150

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 150

Group type: COMPARATOR
Intervention: HIFU
Number of subjects: 150
Study: 34092091

Group type: EXPERIMENTAL
Intervention: CoreValve self-expanding supra-annular TAVR
Number of subjects: 639
Study: 34092097

Group type: EXPERIMENTAL
Intervention: Second transcatheter aortic valve replacement (TAVR)
Number of subjects: 172
Study: 34092119

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34092158

Group type: EXPERIMENTAL
Intervention: Pregabalin pharmacotherapy, dosage and duration not available
Number of subjects: 0
Study: 34092223

Group type: EXPERIMENTAL
Intervention: Multidimensional prevention programme based on temporal patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audits and seminars of healthcare professionals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-Component and Single Cosinor analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative study based on focus groups
Number of subjects: 0
Study: 34092233

Group type: EXPERIMENTAL
Intervention: Rigosertib (RGS) monotherapy (300 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rigosertib (RGS) in combination with αPD1 + αCTLA4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rigosertib (RGS)
Number of subjects: 0
Study: 34092549

Group type: EXPERIMENTAL
Intervention: Combination of subanesthetic intravenous ketamine and therapist-administered e-CBT over 14 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist control group receiving the experimental treatment after 14 weeks
Number of subjects: 20
Study: 34093204

Group type: EXPERIMENTAL
Intervention: Mudan Granule combined with Methylcobalamin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34093444

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment (median dose of 50 μg)
Number of subjects: 842

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 842
Study: 34093762

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 161
Study: 34093873

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 0
Study: 34094549

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL-2) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium and long treatment regimens of low-dose IL-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long treatment regimen of low-dose IL-2
Number of subjects: 0
Study: 34094939

Group type: EXPERIMENTAL
Intervention: Intraoperative B-mode ultrasound guided surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard neuronavigation surgery
Number of subjects: 50
Study: 34095161

Group type: EXPERIMENTAL
Intervention: Electroacupuncture therapy, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 34095178

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 34095266

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) assessment
Number of subjects: 0
Study: 34095450

Group type: EXPERIMENTAL
Intervention: TMAO levels in patients with persistent AF
Number of subjects: 78

Group type: COMPARATOR
Intervention: TMAO levels in patients with paroxysmal AF
Number of subjects: 78
Study: 34096037

Group type: EXPERIMENTAL
Intervention: Rectal water-contrast transvaginal ultrasonography (RWC-TVS)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Sonovaginography (SVG)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: RWC-TVS
Number of subjects: 281

Group type: COMPARATOR
Intervention: RWC-TVS and SVG
Number of subjects: 281
Study: 34096130

Group type: EXPERIMENTAL
Intervention: Social media use for informational support
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Social media use for emotional support
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Information gathering through social media
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Concerns about privacy vs. transparency
Number of subjects: 14
Study: 34096320

Group type: EXPERIMENTAL
Intervention: HIV positive
Number of subjects: 155
Study: 34096341

Group type: EXPERIMENTAL
Intervention: Amplitude Spectral Area (AMSA)
Number of subjects: 50
Study: 34096690

Group type: EXPERIMENTAL
Intervention: Sotorasib (960 mg orally once daily)
Number of subjects: 126
Study: 34096876

Group type: EXPERIMENTAL
Intervention: App-based indoor 6-minute walk test (6MWT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Community-based outdoor 6-minute walk test (6MWT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Usability of the app
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pulse oximetry during 6MWTs
Number of subjects: 30